

*IMSUT Hospital***Department of Oncology and
General Medicine****腫瘍・総合内科**

Head, Professor

Narikazu Boku, M.D., D.M.Sc.

Professor

Hiroshi Yotsuyanagi, M.D., D.M.Sc.

Project Senior Assistant Professor

Koichi Kimura, M.D., D.M.Sc.

Assistant Professor

Keisuke Baba, M.D., D.M.Sc.

教授

博士(医学)

朴

成和

教授

博士(医学)

四

柳

宏

特任講師

博士(医学)

木

村

公一

助教

博士(医学)

馬

場

啓介

The department of oncology and general medicine started in July 2021 taking over the department of general medicine. The members specialize in medical oncology, hepatology, cardiology, endocrinology/metabolism. Our aim is to practice total human medical care including cancer patients in collaboration with other departments in the IMSUT hospital and conduct clinical research.

1. Treatment of patients with advanced cancer.**Boku N, Baba K**

Patients with various, mainly gastrointestinal, cancers were treated by standard chemotherapy including cytotoxic chemotherapy, molecular target agents, immune checkpoint inhibitors, in combination with surgery and radiation therapy. The number of chemotherapy cases has been increasing; 150 chemotherapy regimens for 109 patients in 2024, including 55 new patients. With help of the special patient support team including nurses, pharmacists and nutritionists, the quality and system of patient care during chemotherapy has been improved. We enrolled 8 patients to 8 prospective multi-institutional clinical trials (5 patients in 4 clinical trials for new drug development) (Table). As a result of our in-house clinical trial, topical steroid could reduce the incidence of hand-foot syndrome in colorectal cancer patients receiving adjuvant chemotherapy with capecitabine plus oxaliplatin. As a principal investigator, we are now preparing a multi-institutional randomized

phase III trial comparing topical diclofenac with placebo for preventing capecitabine induced hand-foot syndrome, for which we have achieved a grant from the Japan Agency for Medical Research and Development (AMED). This trial is planned to be launched in April 2025. As a basic research, we investigate the synergism of molecular target agents based on the phosphoproteomic analysis for developing new personalized treatment, for which we have obtained the Grants-in-Aid for Scientific Research from Japan Society for the Promotion of Science.

2. Multicenter clinical and experimental studies of muscular dystrophy.**Kimura K**

Multicenter clinical studies for patients with muscular dystrophy have been conducted in collaboration with NHO (National Hospital Organization) hospitals; Sendai-nishitaga National Hospital (Miyagi), Niigata National Hospital (Niigata), Matsumoto Medical Center (Nagano), Shimoshizu National Hos-

Table: List of on-going clinical trials

Phase I/II study of S-1 at the dose recommended by the BBT formula in combination with oxaliplatin and nivolumab for advanced gastric cancer
Randomized phase II trial of trifluridine/tipiracil plus ramucirumab versus trifluridine/tipiracil in previously treated advanced gastric adenocarcinoma
A phase II study of mFOLFOX6 + Nivolumab as first-line treatment in gastric cancer with severe peritoneal metastasis
A prospective study of triplet therapy with encorafenib, Binimetinib and cetuximab for early relapse BRAF V600E-mutated Stage II/III colorectal cancer during or after adjuvant chemotherapy
A randomized phase III study to compare ONO-4538 in combination with ipilimumab, fluoropyrimidine- and platinum-based chemotherapy versus chemotherapy in advanced gastric cancer
A randomized phase II study to compare ONO-4578 with placebo in combination with nivolumab, fluoropyrimidine- and platinum- based chemotherapy with those of the treatment with placebo in combination with nivolumab and chemotherapy in advanced gastric cancer
A phase 1b/2 study evaluating bezarituzumab in combination with other anti-cancer therapies in advanced gastric cancer
A phase I study of a recombinant measles virus for Nectin-4 (+) tumor

pital (Chiba), Hakone National Hospital (Kanagawa), Osaka-tonoyama Medical Center (Osaka), Iou National Hospital (Ishikawa), Hiroshima-nishi Medical Center (Hiroshima), Akita National Hospital (Akita), and Aomori National Hospital (Aomori). Furthermore, we performed several animal experiments using CRISPR/CAS9 genome-designed rats in collaboration with department of veterinary physiology (The University of Tokyo), Kobe University (Hyogo), and

National Institute of Advanced Industrial Science and Technology (AIST, Ibaraki). Other animal experiments using dogs, pigs and knockout mice were performed in collaboration with National Center of Neurology and Psychiatry (NCNP, Tokyo). We contribute to the publication of Japanese clinical guidelines of Duchenne muscular dystrophy and Fukuyama muscular dystrophy.

Publications

1. Boku N, Omori T, Shitara K, Sakuramoto S, Yamaguchi K, Kato K, Kadowaki S, Tsuji K, Ryu MH, Oh DY, Oh SC, Rha SY, Lee KW, Chung IJ, Sym SJ, Chen LT, Chen JS, Bai LY, Nakada T, Hagihara S, Makino R, Nishiyama E, Kang YK. Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/ gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 trial. *Gastric Cancer*. 27(6):1287-1301, 2024.
2. Yoshikawa T, Terashima M, Mizusawa J, Nunobe S, Nishida Y, Yamada T, Kaji M, Nomura T, Hato S, Choda Y, Yabusaki H, Yoshida K, Misawa K, Masuzawa T, Tsuda M, Kawachi Y, Katayama H, Fukuda H, Kurokawa Y, Boku N, Sano T, Sasako M. 5-year follow-up results of a JCOG1104 (OPAS-1) phase III non-inferiority trial to compare 4 courses and 8 courses of S-1 adjuvant chemotherapy for pathological stage II gastric cancer. *Gastric Cancer*. 27(1): 155-163, 2024.
3. Yamada Y, Nagashima K, Azuma M, Masutani M, Ichikawa H, Iwasa S, Takahashi N, Hirano H, Kanato K, Machida N, Kinoshita T, Hata H, Kawakami H, Takahari D, Boku N, Kurokawa Y, Terashima M, Yoshikawa T, Sekine S, Hiraoka N. Predictive and prognostic value of excision repair cross-complementing group 1 in patients with advanced gastric cancer. *BJC Rep* 2: 18, 2024.
4. Sato R, Tokunaga M, Mizusawa J, Sato Y, Ito S, Takahari D, Sano T, Onaya H, Yoshikawa T, Boku N, Terashima M. Clinical impact of skeletal muscle mass change during the neoadjuvant chemotherapy period in patients with gastric cancer: An ancillary study of JCOG1002. *World J Surg*. 48(1): 163-174, 2024.
5. Kurokawa Y, Doki Y, Kitabayashi R, Yoshikawa T, Nomura T, Tsuji K, Goto M, Cho H, Hihara J, Hiki N, Nunobe S, Mizusawa J, Boku N, Terashima M. Short-term outcomes of preoperative chemotherapy with docetaxel, oxaliplatin, and S-1 for gastric cancer with extensive lymph node metastasis (JCOG1704). *Gastric Cancer*. 27(2): 366-374, 2024.
6. Kang YK, Ryu MH, Di Bartolomeo M, Chau I, Yoon H, Kim JG, Lee KW, Oh SC, Takashima A,

- Kryzhanivska A, Chao Y, Evesque L, Schenker M, McGinn A, Zhao Y, Lee J, Wyrwicz L, Boku N. Rivoceranib, a VEGFR-2 inhibitor, monotherapy in previously treated patients with advanced or metastatic gastric or gastroesophageal junction cancer (ANGEL study): an international, randomized, placebo-controlled, phase 3 trial. *Gastric Cancer*. 27(2): 375-386, 2024.
7. Taki Y, Ito S, Mizusawa J, Yura M, Sato Y, Nomura T, Tsuda M, Omori T, Kunisaki C, Choda Y, Cho H, Hiki N, Boku N, Yoshikawa T, Katai H, Terashima M. Risk factors for abdominal surgical infectious complications after distal gastrectomy for gastric cancer: A post-hoc analysis of a randomized controlled trial (JCOG0912). *Eur J Surg Oncol*. 2024 Jan 24;50(3):107982.
 8. Matsumoto T, Yamamoto Y, Kotaka M, Masuishi T, Tsuji Y, Shoji H, Hirata K, Tsuduki T, Makiyama A, Izawa N, Takahashi N, Tsuda M, Yasui H, Ohta T, Kito Y, Otsu S, Hironaka S, Yamazaki K, Boku N, Hyodo I, Yoshimura K, Muro K. A Phase II Study of FOLFIRI Plus Ziv-Aflibercept After Trifluridine/Tipiracil Plus Bevacizumab in Patients with Metastatic Colorectal Cancer: WJOG 11018G. *Target Oncol*. 19(2): 181-190, 2024.
 9. Oshima K, Shoji H, Boku N, Hirano H, Okita N, Takashima A, Kato K, Kudo-Saito C. CRP and soluble CTLA4 are determinants of anti-PD1 resistance in gastrointestinal cancer. *Am J Cancer Res*. 14(3): 1174-1189, 2024
 10. Arai H, Tsuda T, Sunakawa Y, Shimokawa M, Akiyoshi K, Tokunaga S, Shoji H, Kunieda K, Kotaka M, Matsumoto T, Nagata Y, Mizukami T, Mizuki F, Danenberg KD, Boku N, Nakajima TE. Switching from FOLFIRI plus cetuximab to FOLFIRI plus bevacizumab based on early tumor shrinkage in RAS wild-type metastatic colorectal cancer: A phase II trial (HYBRID). *Cancer Med*. e7107, 2024.
 11. Cho H, Abe S, Nonaka S, Suzuki H, Yoshinaga S, Okuma K, Yamamoto S, Daiko H, Kato K, Sekine S, Boku N, Saito Y. Long-term outcomes after non-curative endoscopic resection for esophageal squamous cell carcinoma followed by additional chemoradiotherapy. *Dis Esophagus*. 37(5): doae 004, 2024.
 12. Tokunaga M, Machida N, Mizusawa J, Ito S, Yabusaki H, Hirao M, Watanabe M, Imamura H, Kinoshita T, Yasuda T, Hihara J, Fukuda H, Yoshikawa T, Boku N, Terashima M. Early endpoints of a randomized phase II trial of preoperative chemotherapy with S-1/CDDP with or without trastuzumab followed by surgery for HER2-positive resectable gastric or esophagogastric junction adenocarcinoma with extensive lymph node metastasis: Japan Clinical Oncology Group study JCOG1301C (Trigger Study). *Gastric Cancer*. 27(3): 580-589, 2024.
 13. Obama K, Fujimori M, Boku N, Matsuoka A, Mori K, Okizaki A, Miyaji T, Okamura M, Majima Y, Goto S, Shimazu T, Uchitomi Y. Shared decision-making support program for older patients with advanced cancer using a question prompt list and geriatric assessment: A pilot randomized controlled trial. *J Geriatr Oncol*. 15(5): 101778, 2024.
 14. Kobayashi M, Kako J, Iba A, Okuyama A, Ozawa K, Abe M, Wada M, Akechi T, Iihara H, Imamura CK, Kim YI, Sasaki H, Satomi E, Takeda M, Tanaka R, Nakajima TE, Nakamura N, Nishimura J, Noda M, Hayashi K, Higashi T, Boku N, Matsumoto K, Matsumoto Y, Okita K, Yamamoto N, Aogi K, Iino K. Non-pharmacological treatments for anticipatory nausea and vomiting during chemotherapy: a systematic review and meta-analysis of the Clinical Practice Guidelines for Antiemesis 2023. *Int J Clin Oncol*. 29(7): 889-898, 2024.
 15. Iihara H, Abe M, Wada M, Iino K, Akechi T, Imamura CK, Okuyama A, Ozawa K, Kim YI, Sasaki H, Satomi E, Takeda M, Tanaka R, Nakajima TE, Nakamura N, Nishimura J, Noda M, Hayashi K, Higashi T, Boku N, Matsumoto K, Matsumoto Y, Okita K, Yamamoto N, Aogi K. 2023 Japan Society of clinical oncology clinical practice guidelines update for antiemesis. *Int J Clin Oncol*. 29(7): 873-888, 2024.
 16. Fukuda K, Osumi H, Yoshinami Y, Ooki A, Takashima A, Wakatsuki T, Hirano H, Nakayama I, Ouchi K, Sawada R, Fukuoka S, Ogura M, Takahashi D, Chin K, Shoji H, Okita N, Kato K, Ishizuka N, Boku N, Yamaguchi K, Shinozaki E. Efficacy of anti-epidermal growth factor antibody rechallenge in RAS/BRAF wild-type metastatic colorectal cancer: a multi-institutional observational study. *J Cancer Res Clin Oncol*. 150(7): 369, 2024.
 17. Kang YK, Terashima M, Kim YW, Boku N, Chung HC, Chen JS, Ji J, Yeh TS, Chen LT, Ryu MH, Kim JG, Omori T, Rha SY, Kim TY, Ryu KW, Sakuramoto S, Nishida Y, Fukushima N, Yamada T, Bai LY, Hirashima Y, Hagihara S, Nakada T, Sasako M. Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. *Lancet Gastroenterol Hepatol*. 9(8): 705-717, 2024.
 18. Hayashi M, Yoshikawa T, Mizusawa J, Hato S, Iwasaki Y, Sasako M, Kawachi Y, Iishi H, Choda Y, Boku N, Terashima M. Prognostic Impact of Post-operative Infectious Complications in Gastric Cancer Patients Receiving Neoadjuvant Chemotherapy: Post Hoc Analysis of a Randomized Controlled Trial, JCOG0501. *J Gastrointest Cancer*. 55(3): 1125-1133, 2024.
 19. Yamaguchi T, Kumagai K, Yagi S, Nomura T, Nagashima K, Watanabe M, Makuuchi R, Kawakami K, Matsushima T, Kadowaki S, Haruta S, Cho H, Kakihara N, Otsuka S, Yamada T, Imai Y, Boku N.

- Efficacy of chemotherapy for patients with gastric cancer with early recurrence during or after adjuvant chemotherapy with S-1 alone: a multicenter retrospective study. *Sci Rep.* 14(1):21854, 2024.
20. Shoji H, Hirano H, Nojima Y, Gunji D, Shinkura A, Muraoka S, Abe Y, Narumi R, Nagao C, Aoki M, Obama K, Honda K, Mizuguchi K, Tomonaga T, Saito Y, Yoshikawa T, Kato K, Boku N, Adachi J. Phosphoproteomic subtyping of gastric cancer reveals dynamic transformation with chemotherapy and guides targeted cancer treatment. *Cell Rep.* 2024 Sep 25: Online ahead of print.
 21. Kudo-Saito C, Imazeki H, Ozawa H, Kawakubo H, Hirano H, Boku N, Kato K, Shoji H. Targeting SNCA in the treatment of malignant ascites in gastrointestinal cancer. *Transl Oncol.* 48: 102075, 2024.
 22. Nishina T, Boku N, Kurokawa Y, Sasaki K, Machida R, Yoshikawa T. A real-world survey on expensive drugs used as first-line chemotherapy in patients with HER2-negative unresectable advanced/recurrent gastric cancer in the stomach cancer study group of the Japan clinical oncology group. *Jpn J Clin Oncol.* 54(10):1100-1106, 2024
 23. Shoji H, Hirano H, Nojima Y, Gunji D, Shinkura A, Muraoka S, Abe Y, Narumi R, Nagao C, Aoki M, Obama K, Honda K, Mizuguchi K, Tomonaga T, Saito Y, Yoshikawa T, Kato K, Boku N, Adachi J. Phosphoproteomic subtyping of gastric cancer reveals dynamic transformation with chemotherapy and guides targeted cancer treatment. *Cell Rep.* 43(10): 114774, 2024.
 24. Hayashi T, Yamamoto S, Miyata Y, Takeda M, Abe M, Wada M, Iino K, Akechi T, Imamura CK, Okuyama A, Ozawa K, Kim YI, Sasaki H, Satomi E, Tanaka R, Nakajima TE, Nakamura N, Nishimura J, Noda M, Hayashi K, Higashi T, Boku N, Matsumoto K, Matsumoto Y, Okita K, Yamamoto N, Aogi K, Iihara H. Defining the clinical benefits of adding a neurokinin-1 receptor antagonist to control chemotherapy-induced nausea and vomiting in moderately emetogenic chemotherapy: a systematic review and meta-analysis of the clinical practice guidelines for antiemesis 2023 from the Japan society of clinical oncology. *Int J Clin Oncol.* 29(11): 1616-1631, 2024.
 25. Yokomizo A, Nakashima K, Iba A, Okita K, Wada M, Iino K, Akechi T, Iihara H, Imamura CK, Okuyama A, Ozawa K, Kim YI, Sasaki H, Satomi E, Takeda M, Tanaka R, Nakajima TE, Nakamura N, Nishimura J, Noda M, Hayashi K, Higashi T, Boku N, Matsumoto K, Matsumoto Y, Yamamoto N, Aogi K, Abe M. Efficacy and safety of dexamethasone sparing for the prevention of nausea and vomiting associated with highly emetogenic risk antineoplastic agents: a systematic review and meta-analysis of the Clinical Practice Guidelines for Antiemesis 2023 from the Japan Society of Clinical Oncology. *Int J Clin Oncol.* 29(11): 1632-1640, 2024.
 26. Shoji H, Kudo-Saito C, Nagashima K, Imazeki H, Tsugaru K, Takahashi N, Kawakami T, Amanuma Y, Wakatsuki T, Okano N, Narita Y, Yamamoto Y, Kizawa R, Muro K, Aoki K, Boku N. Myeloid subsets impede the efficacy of anti-PD1 therapy in patients with advanced gastric cancer (WJOG-10417GTR study). *J Immunother Cancer.* 12(11): e010174, 2024.
 27. Baba K, Tanie T, Matsubara Y, Hirata Y, Ikematsu H, Imamura CK, Boku N. Concentrations of Irinotecan and SN-38 in the Ascites and the Fluid Product of Cell-Free and Concentrated Ascites Reinfusion Therapy 9 Days After Administration of Irinotecan in a Patient with Gastric Cancer: A Case Report. *OncoTargets and Therapy* 17: 1089–1094, 2024
 28. Matsubara Y, Ota Y, Denda T, Tanaka Y, Isobe M, Kato S, Konuma T, Takahashi S, Hirata Y, Ikematsu H, Baba K, Boku N. Both Th1 and Th2 CD4 + T-Cell Lineage Infiltrations Decrease in Post-hematopoietic Stem Cell Transplantation Colon Adenoma. *J Gastrointest Cancer.* 55(4):1551-1558, 2024.
 29. Nakashima K, Yokomizo A, Murakami M, Okita K, Wada M, Iino K, Akechi T, Iihara H, Imamura CK, Okuyama A, Ozawa K, Kim YI, Sasaki H, Satomi E, Takeda M, Tanaka R, Nakajima TE, Nakamura N, Nishimura J, Noda M, Hayashi K, Higashi T, Boku N, Matsumoto K, Matsumoto Y, Yamamoto N, Aogi K, Abe M. Efficacy and safety of dexamethasone sparing for the prevention of nausea and vomiting associated with moderately emetogenic chemotherapy: a systematic review and meta-analysis of Clinical Practice Guidelines for Antiemesis 2023 from Japan Society of Clinical Oncology. *Int J Clin Oncol.* 29(12): 1785-1794, 2024.
 30. Kita R, Yasufuku I, Takahashi N, Mizusawa J, Sano Y, Fukuda H, Kurokawa Y, Boku N, Terashima M, Yoshikawa T; Stomach Cancer Study Group of the Japan Clinical Oncology Group. Randomized controlled phase III study comparing chemotherapy alone versus conversion surgery after a remarkable response to chemotherapy in patients with initially unresectable cStage IVB or pStage IV gastric cancer (JCOG2301, Conversion study). *Jpn J Clin Oncol.* 2024 Dec 18. Online ahead of print.
 31. Komori A, Hironaka S, Kadowaki S, Mitani S, Furuta M, Kawakami T, Makiyama A, Takegawa N, Sugiyama K, Hirano H, Ando T, Matsushima T, Chida A, Kashiwada T, Komoda M, Matsumoto T, Oda H, Yabusaki H, Kawakami H, Yamazaki K, Boku N, Hyodo I, Yoshimura K, Muro K; West Japan Oncology Group (WJOG). Prevalence and clinicopathological features of microsatellite instability-high metastatic or recurrent gastric and esophagogastric junction cancer: WJOG13320GPS. *Gastric Cancer.* 2024 Dec 31. Online ahead of print.
 32. Kimura K, Wakisaka A, Morita H, Nakanishi K,

- Daimon M, Nojima M, Itoh H, Takeda A, Kitao R, Imai T, Ikeda T, Nakajima T, Watanabe C, Furukawa T, Ohno I, Ishida C, Takeda N, Komai K. Efficacy and tolerability of ivabradine for cardiomyopathy in patients with Duchenne muscular dystrophy – one year treatment results in Japanese National Hospitals. *Int Heart J.* 65: 211-217, 2024.
33. Otake M, Imamura M, Enya S, Kangawa A, Shibata M, Ozaki K, Kimura K, Ono E, Aoki Y. Severe cardiac and skeletal manifestations in DMD-edited microminipigs: an advanced surrogate for Duchenne muscular dystrophy. *Commun Biol.* 71: 523, 2024.
34. Kimura K, Morita H, Nakanishi K, Daimon M, Nakamura A, Matsumura T, Takeda A, Ito H, Okada T, Takeda N. Treatment strategy for cardiomyopathy of Duchenne muscular dystrophy. *Neurological Therapeutics.* 41: 434-436, 2024.
35. Kimura K, Tochinai R, Saika T, Fujii W, Morita H, Nakanishi K, Tsuru Y, Sekizawa S, Yamanouchi K, Kuwahara M. Ivabradine ameliorates cardiomyopathy progression in a Duchenne muscular dystrophy model rat. *Exp Anim.* 73: 145-153, 2024.
36. Nakamura A, Matsumura T, Ogata K, Mori-Yoshimura M, Takeshita E, Kimura K, Arahata H, Takeshima Y, Takahashi T, Ishigaki K, Awano H, Sugie K, Fujii T, Oi H, Komaki H. Clinical characteristics of patients with Becker muscular dystrophy having pathogenic microvariants or duplications. *Neurol Genet.* 11: e200215, 2024.
37. M Rui, Nakanishi K, Nakao T, Hirokawa M, Kimura K, Suzuki H, Yatomi Y, Daimon M. Three-dimensional Geometry Values and Clinical Determinants for the Annulus of the Tricuspid Valve in a Japanese population: A Real-time Three-dimensional Echocardiographic Analysis. *Int Heart J.* 65: 808-816, 2024.
38. Awano H, Nambu Y, Osawa K, Shirakawa T, Matsumura T, Wakisaka A, Kuru S, Funato M, Takeshima Y, Ishigaki K, Kobayashi M, Sato T, Fujii T, Sugie K, Kimura K, Komaki H, Nakamura A, Matsuo M. Urinary titin reflects the severity of walking ability, muscle strength, and muscle and cardiac damage in patients with Becker muscular dystrophy. *Clinica Chimica Acta.* In Press.
39. Matsumura T, Fukudome T, Motoyoshi Y, Nakamura A, Kuru S, Segawa K, Kitao R, Watanabe C, Tamura T, Takahashi T, Hashimoto H, Sekimizu M, Saito AM, Asakura M, Kimura K, Iwata Y. Efficacy of tranilast in preventing exacerbating cardiac function and death from heart failure in muscular dystrophy patients with advanced-stage heart failure: A single-arm, open-label, multicenter study. *Orphanet J Rare Dis.* In Press.
40. Itoh H, Hisamatsu T, Segawa K, Takahashi T, Sato T, Takada H, Kuru S, Wada C, Suzuki M, Tamura T, Suwazono S, Kimura K, Matsumura T, Takahashi M. CTG Repeat Length Underlying Cardiac Events and Sudden Death in Myotonic Dystrophy Type 1. *Eur Heart J Open.* 18: oeae078, 2024.